The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification

Journal of Virology

Volumn 84, Issue 20, 2010, Pages 10619-10629

  Suprynowicz, Frank A ^a   Krawczyk, Ewa ^a   Hebert, Jess D ^a   Sudarshan, Sawali R ^a   Simic, Vera ^a   Kamonjoh, Christopher M ^a   Schlegel, Richard ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAFILOMYCIN A1; EPIDERMAL GROWTH FACTOR; HUMAN PAPILLOMAVIRUS TYPE 16 E5 ONCOPROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG;

ACIDIFICATION; ALKALINIZATION; ARTICLE; CELL MIGRATION; CELL SURFACE; CYTOSKELETON; ENDOCYTOSIS; ENDOSOME; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; KERATINOCYTE; MEMBRANE FUSION; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; ENDOSOMES; EPIDERMAL GROWTH FACTOR; HOST-PATHOGEN INTERACTIONS; HUMAN PAPILLOMAVIRUS 16; HUMANS; HYDROGEN-ION CONCENTRATION; ONCOGENE PROTEINS, VIRAL; PROTON-TRANSLOCATING ATPASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VIRUS INTERNALIZATION;

HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 77957201861     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00831-10     Document Type: Article

References (64)

1. +-ATPase is not sufficient for biological activity, using mammalian and yeast expression systems. Virology 272:315-325.
2. +-ATPase mutants transform cells and define a binding site for the papillomavirus E5 oncoprotein. J. Biol. Chem. 270:6830-6837.
3. Annaert, W. G., B. Becker, U. Kistner, M. Reth, and R. Jahn. 1997. Export of cellubrevin from the endoplasmic reticulum is controlled by BAP31. J. Cell Biol. 139:1397-1410. (Pubitemid 28013661)
4. Arbeit, J. M., K. Munger, P. M. Howley, and D. Hanahan. 1994. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol. 68:4358-4368.
5. +-ATPase. J. Gen. Virol. 82:2353-2362.
6. Ashrafi, G. H., M. Haghshenas, B. Marchetti, and M. S. Campo. 2006. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int. J. Cancer 119: 2105-2112.
7. Bouvard, V., G. Matlashewski, Z. M. Gu, A. Storey, and L. Banks. 1994. The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology 203:73-80. (Pubitemid 24260023)
8. Bowman, B. J., and E. J. Bowman. 2002. Mutations in subunit c of the vacuolar ATPase confer resistance to bafilomycin and identify a conserved antibiotic binding site. J. Biol. Chem. 277:3965-3972.
9. Bowman, E. J., A. Siebers, and K. Altendorf. 1988. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc. Natl. Acad. Sci. U. S. A. 85:7972-7976.
10. +-ATPase function and stability in Saccharomyces cerevisiae. Virology 280:169-175.
11. +-ATPase is a novel sarcoglycan-interacting protein. Biochim. Biophys. Acta 1772:570-579.
12. Choo, K. B., C. C. Pan, M. S. Liu, H. T. Ng, C. P. Chen, Y. N. Lee, C. F. Chao, C. L. Meng, M. Y. Yeh, and S. H. Han. 1987. Presence of episomal and integrated human papillomavirus DNA sequences in cervical carcinoma. J. Med. Virol. 21:101-107.
13. Clifford, G. M., J. S. Smith, M. Plummer, N. Munoz, and S. Franceschi. 2003. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88:63-73.
14. Conrad, M., V. J. Bubb, and R. Schlegel. 1993. The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J. Virol. 67:6170-6178. (Pubitemid 23277529)
15. Crusius, K., E. Auvinen, B. Steuer, H. Gaissert, and A. Alonso. 1998. The human papillomavirus type 16 E5 protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp. Cell Res. 241:76-83.
16. Cullen, A. P., R. Reid, M. Campion, and A. T. Lorincz. 1991. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J. Virol. 65:606-612.
17. Disbrow, G. L., J. A. Hanover, and R. Schlegel. 2005. Endoplasmic reticulum- localized human papillomavirus type 16 E5 protein alters endosomal pH but not trans-Golgi pH. J. Virol. 79:5839-5846.
18. Disbrow, G. L., I. Sunitha, C. C. Baker, J. Hanover, and R. Schlegel. 2003. Codon optimization of the HPV-16 E5 gene enhances protein expression. Virology 311:105-114.
19. D'Souza-Schorey, C., G. Li, M. I. Colombo, and P. D. Stahl. 1995. A regulatory role for ARF6 in receptor-mediated endocytosis. Science 267:1175-1178.
20. Fehrmann, F., and L. A. Laimins. 2003. Human papillomaviruses: targeting differentiating cells for malignant transformation,. Oncogene 22: 5201-5207.
21. Genther-Williams, S. M., G. L. Disbrow, R. Schlegel, D. Lee, D. W. Threadgill, and P. F. Lambert. 2005. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res. 65:6534-6542.
22. Gieswein, C. E., F. J. Sharom, and A. G. Wildeman. 2003. Oligomerization of the E5 protein of human papillomavirus type 16 occurs through multiple hydrophobic regions. Virology 313:415-426.
23. Gruenberg, J., and F. R. Maxfield. 1995. Membrane transport in the endocytic pathway. Curr. Biol. 7:552-563.
24. Hafner, N., C. Driesch, M. Gajda, L. Jansen, R. Kirchnayr, I. B. Runnebaum, and M. Durst. 2008. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 27: 1610-1617. (Pubitemid 351347875)
25. Hu, L., and B. P. Ceresa. 2009. Characterization of the plasma membrane localization and orientation of HPV16 E5 for cell-cell fusion. Virology 393:135-143.
26. Hu, L., K. Plafker, V. Vorozhko, R. E. Zuna, M. H. Hanigan, G. J. Gorbsky, S. M. Plafker, P. C. Angeletti, and B. P. Ceresa. 2009. Human papillomavirus 16 E5 induces bi-nucleated cell formation by cell-cell fusion. Virology 384: 125-134.
27. Hurtado-Lorenzo, A., M. Skinner, J. El Annan, M. Futai, G. H. Sun-Wada, S. Bourgoin, J. Casanova, A. Wildeman, S. Bechoua, D. A. Ausiello, D. Brown, and V. Marshansky. 2006. V-ATPase interacts with ARNO and Arf6 in early endosomes and regulates the protein degradative pathway. Nat. Cell Biol. 8:124-136.
28. +)-ATPases. Arch. Biochem. Biophys. 476:33-42.
29. Kim, J. H., L. Johannes, B. Goud, C. Antony, C. A. Lingwood, R. Daneman, and S. Grinstein. 1998. Noninvasive measurement of the pH of the endoplasmic reticulum at rest and during calcium release. Proc. Natl. Acad. Sci. U. S. A. 95:2997-3002.
30. Krawczyk, E., J. A. Hanover, R. Schlegel, and F. A. Suprynowicz. 2008. Karyopherin β3: a new cellular target for the HPV-16 E5 oncoprotein. Biochem. Biophys. Res. Commun. 371:684-688.
31. Krawczyk, E., F. A. Suprynowicz, X. Liu, Y. Dai, D. P. Hartmann, J. Hanover, and R. Schlegel. 2008. Koilocytosis: a cooperative interaction between the human papillomavirus E5 and E6 oncoproteins. Am. J. Pathol. 173:682-688.
32. Krawczyk, E., F. A. Suprynowicz, S. R. Sudarshan, and R. Schlegel. 2010. Membrane orientation of the human papillomavirus type 16 E5 oncoprotein. J. Virol. 84:1696-1703.
33. Leechanachai, P., L. Banks, F. Moreau, and G. Matlashewski. 1992. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene 7:19-25.
34. Lim, P. S., A. B. Jenson, L. Cowsert, Y. Nakai, L. Y. Lim, X. W. Jin, and J. P. Sundberg. 1990. Distribution and specific identification of papillomavirus major capsid protein epitopes by immunocytochemistry and epitope scanning of synthetic peptides. J. Infect. Dis. 162:1263-1269.
35. Maranda, B., D. Brown, S. Bourgoin, J. E. Casanova, P. Vinay, D. A. Ausiello, and V. Marshansky. 2001. Intra-endosomal pH-sensitive recruitment of the Arf-nucleotide exchange factor ARNO and Arf6 from cytoplasm to proximal tubule endosomes. J. Biol. Chem. 276:18540-18550.
36. Matsukura, T., S. Koi, and K. Sugase. 1989. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology 172:63-72. (Pubitemid 19221436)
37. Oelze, I., J. Kartenbeck, K. Crusius, and A. Alonso. 1995. Human papillomavirus type 16 E5 protein affects cell-cell communication in an epithelial cell line. J. Virol. 69:4489-4494.
38. Pati, U. K. 1992. Novel vectors for expression of cDNA encoding epitope-tagged proteins in mammalian cells. Gene 114:285-288.
39. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. U. S. A. 90:8392-8396.
40. Pedroza-Saavedra, A., E. W. Lam, F. Esquivel-Guadarrama, and L. Gutierrez- Xicotencatl. 2010. The human papillomavirus type 16 E5 oncoprotein synergizes with EGF-receptor signaling to enhance cell cycle progression and the downregulation of p27Kip1. Virology 400:44-52.
41. Pim, D., M. Collins, and L. Banks. 1992. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 7:27-32.
42. Pirami, L., V. Giache, and A. Becciolini. 1997. Analysis of HPV16, 18, 31, and 35 DNA in pre-invasive and invasive lesions of the uterine cervix. J. Clin. Pathol. 50:600-604.
43. Regan, J. A., and L. A. Laimins. 2008. Bap31 is a novel target of the human papillomavirus E5 protein. J. Virol. 82:10042-10051.
44. Riley, R. R., S. Duensing, T. Brake, K. Munger, P. F. Lambert, and J. M. Arbeit. 2003. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 63:4862-4871.
45. Roberts, R. L., M. A. Barbieri, J. Ullrich, and P. D. Stahl. 2000. Dynamics of rab5 activation in endocytosis and phagocytosis. J. Leukoc. Biol. 68: 627-632.
46. +-ATPase can be dissociated from the E5-mediated epidermal growth factor receptor overactivation. Oncogene 19:3727-3732.
47. Schapiro, F., J. Sparkowski, A. Adduci, F. Suprynowicz, R. Schlegel, and S. Grinstein. 2000. Golgi alkalinization by the papillomavirus E5 oncoprotein. J. Cell Biol. 148:305-315.
48. Schiffman, M., R. Herrero, R. Desalle, A. Hildesheim, S. Wacholder, A. C. Rodriguez, M. C. Bratti, M. E. Sherman, J. Morales, D. Guillen, M. Alfaro, M. Hutchinson, T. C. Wright, D. Solomon, Z. Chen, J. Schussler, P. E. Castle, and R. D. Burk. 2005. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337:76-84.
49. Schlegel, R., W. C. Phelps, Y. L. Zhang, and M. Barbosa. 1988. Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. EMBO J. 7:3181-3187.
50. Sparkowski, J., J. Anders, and R. Schlegel. 1994. Mutation of the bovine papillomavirus E5 oncoprotein at amino acid 17 generates both high- and low-transforming variants. J. Virol. 68:6120-6123. (Pubitemid 24258637)
51. Straight, S. W., B. Herman, and D. J. McCance. 1995. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J. Virol. 69:3185-3192.
52. Straight, S. W., P. M. Hinkle, R. J. Jewers, and D. J. McCance. 1993. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J. Virol. 67:4521-4532.
53. Suprynowicz, F. A., M. S. Campo, and R. Schlegel. 2006. Biological activities of papillomavirus E5 proteins, p. 97-113. In M. S. Campo (ed.), Papillomavirus research: from natural history to vaccines and beyond. Caister Academic Press, Wymondham, United Kingdom.
54. Suprynowicz, F. A., G. L. Disbrow, E. Krawczyk, V. Simic, K. Lantzky, and R. Schlegel. 2008. HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells. Oncogene 27:1071-1078.
55. Suprynowicz, F. A., G. L. Disbrow, V. Simic, and R. Schlegel. 2005. Are transforming properties of the bovine papillomavirus E5 protein shared by E5 from high-risk human papillomavirus type 16? Virology 332:102-113.
56. Suprynowicz, F. A., J. Sparkowski, A. Baege, and R. Schlegel. 2000. E5 oncoprotein mutants activate phosphoinositide 3-kinase independently of platelet-derived growth factor receptor activation. J. Biol. Chem. 275: 5111-5119.
57. Thomsen, P., B. van Deurs, B. Norrild, and L. Kayser. 2000. The HPV16 E5 oncogene inhibits endocytic trafficking. Oncogene 19:6023-6032. (Pubitemid 32039376)
58. Tomakidi, P., H. Cheng, A. Kohl, G. Komposch, and A. Alonso. 2000. Connexin 43 expression is downregulated in raft cultures of human keratinocytes expressing the human papillomavirus type 16 E5 protein. Cell Tissue Res. 301:323-327. (Pubitemid 30601563)
59. Tsai, T. C., and S. L. Chen. 2003. The biochemical and biological functions of human papillomavirus type 16 E5 protein. Arch. Virol. 148:1445-1453.
60. Valle, G. F., and L. Banks. 1995. The human papillomavirus (HPV)-6 and HPV-16 E5 proteins cooperate with HPV-16 E7 in the transformation of primary rodent cells. J. Gen. Virol. 76:1239-1245.
61. Visser Smit, G. D., T. L. Place, S. L. Cole, K. A. Clausen, S. Vemuganti, G. Zhang, J. G. Koland, and N. L. Lill. 2009. Cbl controls EGFR fate by regulating early endosome fusion. Sci. Signal. 2:ra86.
62. Wada, Y., G. H. Sun-Wada, H. Tabata, and N. Kawamura. 2008. Vacuolar-type proton ATPase as a regulator of membrane dynamics in multicellular organisms. J. Bioenerg. Biomembr. 40:53-57.
63. Walboomers, J. M., M. V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, K. V. Shah, P. J. Snijders, J. Peto, C. J. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
64. zur Hausen, H., and E. M. de Villiers. 1994. Human papillomaviruses. Annu. Rev. Microbiol. 48:427-447.